Compared with placebo, fostamatinib did not increase the number of oxygen-free days among adults hospitalized with COVID-19 and hypoxemia.

Rigel的研究性化合物R289已获FDA授予骨髓增生异常综合征治疗的孤儿药资格，目前正在进行1b期临床研究。此外，Rigel的药物R289获得FDA快速通道资格用于MDS治疗，突显了该药物改善患者预后的潜力。

Rigel Pharmaceuticals has enrolled the first patient in a Phase I trial to evaluate fostamatinib as a treatment for sickle ...

This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating ...

Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...

Patients will receive oral fostamatinib at a dose of 100 mg twice daily for 14 days, which will be escalated to 150 mg twice daily for an additional 28 days if tolerated. The primary objective ...